Teva pioneering a biosimilar to compete with blockbuster Rituxan

Teva Pharmaceutical is taking aim at Roche's blockbuster Rituxan, confirming reports that it is developing a biosimilar of the monoclonal antibody. Bloomberg reports that Teva appears to be on track to develop the first monoclonal antibody follow-on, one of the pioneers in a coming wave of biosimilars that is expected to start gaining approval around 2013 and 2014. Teva is studying TL011 as a replacement biologic for rheumatoid arthritis patients now on Rituxan. The therapy, Roche's second...